BioTuesdays

Category - Markets

Sensus Healthcare Logo

AGP ups Sensus Healthcare PT to $7.50 from $2.95

Alliance Global Partners raised its price target for Sensus Healthcare (NASDAQ:SRTS) to $7.50 from $2.95, citing fourth quarter results that were well ahead of consensus estimates. The stock closed at $4.94 on March 1...

Cantor starts DarioHealth at OW; PT $35

Cantor Fitzgerald launched coverage of DarioHealth (NASDAQ:DRIO) with an “overweight” rating and price target of $35. The stock closed at $29.16 on Feb. 24. Dario is a digital health company that is developing and...

Lensar

SVB Leerink starts Lensar at OP; PT $20

SVB Leerink initiated coverage of Lensar (NASDAQ:LNSR) with an “outperform” rating and price target of $20. The stock closed at $9.50 on Feb. 23. Lensar was recently spun out from PDL Biopharma and is, “in our view, an...

TransMedics logo

Cowen ups TransMedics PT to $44 from $20

Cowen raised its price target for TransMedics (NASDAQ:TMDX) to $44 from $20, citing multiple catalysts ahead for all three of the company’s organ programs. The stock closed at $23.82 on Feb. 23. TransMedics has...

BTIG ups MannKind PT to $8 from $4

BTIG raised its price target for MannKind (NASDAQ:MNKD) to $8 from $4, citing a recent meeting with MannKind CEO, Michael Castagna, to hear an extensive discussion on Technosphere and Tyvaso DPI expansion, among other...

Cantor cuts Otonomy PT to $6 from $13

Cantor Fitzgerald slashed its price target for Otonomy (NASDAQ:OTIC) to $6 from $13 but maintained its “overweight” rating, after the company announced that the Phase 3 study of OTIVIDEX in Ménière’s disease did not...

Evolus

Cantor ups Evolus PT to $20 from $11

Cantor Fitzgerald raised its price target for Evolus (NASDAQ:EOLS) to $20 from $11, following a litigation settlement, which Cantor believes “increases earnings visibility for Evolus, and removes a large overhang on the...